16 November 2026
To further strengthen regional supply resilience and diversify manufacturing capacity, MPP has launched a targeted regional Expression of Interest (EOI), open exclusively to eligible manufacturers from the Latin American and Caribbean region, to recruit one additional licensee for baloxavir marboxil, an innovative antiviral treatment for influenza recommended by the World Health Organization (WHO).
In May 2026, MPP and Roche signed a voluntary licence agreement to expand access to baloxavir marboxil that will enable generic manufacturers to develop, produce, and supply baloxavir in 129 low- and middle-income countries (LIMCs). The agreement aims to expand access to baloxavir marboxil in LMICs, supporting both seasonal influenza treatment and broader pandemic preparedness and response efforts. Following a global EoI, MPP announced in September the sublicensees selected for manufacturing and supply of the product.
Building on this global licensing initiative, MPP is now seeking one additional licensee based in Latin America and the Caribbean to further strengthen regional manufacturing capacity and supply resilience. The Pan American Health Organization (PAHO) is supporting broader regional engagement around this initiative.
To support interested manufacturers in preparing their applications, MPP and PAHO will jointly host an information webinar on 1 December 2026, from 15:00 to 16:00 CET. The session will cover the licensing opportunity, application requirements and EOI portal, followed by a Q&A. Further details and registration information are provided below.
The EOI is open until 15 December 2026, at 23:59 (Central European Time).
How to apply
Eligible manufacturers interested in applying should follow these steps:
Further details on the EOI process are available at the following link
Information Webinar – Regional Baloxavir Marboxil EOI
The Medicines Patent Pool (MPP), in collaboration with the Pan American Health Organization (PAHO), invites manufacturers from Latin America and the Caribbean to an information webinar to learn more about the regional Expression of Interest (EOI) for baloxavir marboxil. Participants will receive an overview of the licensing opportunity, practical guidance on preparing and submitting an application, and a walkthrough of MPP’s EOI portal. The session will conclude with an opportunity to ask questions.
Date: Tuesday, 1 December 2026
Time: 15:00–16:00 CET
Participation is limited to manufacturers based in Latin America and the Caribbean.
Register for the webinar here
More about Baloxavir marboxil licence
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.